IART — Integra LifeSciences Holdings Corporation stock price, charts and financials
QT74Integra LifeSciences Holdings CorporationIntegra LifeSciences Holdings Corporation (NASDAQ: IART) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.09 | Insider Own | 17.34% | Shs Outstand | 77.77M | Perf Week | -1.81% |
| Market Cap | 1.18B | Forward P/E | 5.83 | EPS next Y | 2.61 | Insider Trans | 0.00% | Shs Float | 58.67M | Perf Month | -11.72% |
| Enterprise Value | 2.94B | PEG | - | EPS next Q | 0.56 | Inst Own | - | Short Float | 11.69% | Perf Quarter | -13.42% |
| Income | -8.00M | P/S | 0.72 | EPS this Y | 2829.81% | Inst Trans | - | Short Ratio | 7.85 | Perf Half Y | 71.01% |
| Sales | 1.65B | P/B | 1.13 | EPS next Y | 6.18% | ROA | -0.20% | Short Interest | 6.86M | Perf YTD | 22.54% |
| Book/sh | 13.51 | P/C | 4.32 | EPS next 5Y | 6.88% | ROE | -0.69% | 52W High | 20.49 -25.72% | Perf Year | 2.84% |
| Cash/sh | 3.52 | P/FCF | 31.11 | EPS past 3/5Y | - | ROIC | 19.92% | 52W Low | 8.70 74.94% | Perf 3Y | -61.08% |
| Dividend Est. | - | EV/EBITDA | 11.79 | Sales past 3/5Y | 1.62% 3.57% | Gross Margin | 53.74% | Volatility | 4.47% 3.73% | Perf 5Y | -78.33% |
| Dividend TTM | - | EV/Sales | 1.78 | EPS Y/Y TTM | 0.22% | Oper. Margin | 39.81% | ATR (14) | 0.71 | Perf 10Y | -65.17% |
| Dividend Ex-Date | - | Quick Ratio | 1.98 | Sales Y/Y TTM | 2.30% | Profit Margin | -0.44% | RSI (14) | 35.16 | Recom | 2.73 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.40 | EPS Q/Q | 24.44% | SMA20 | -6.53% | Beta | 1.21 | Target Price | 20.50 |
| Payout | 0.00% | Debt/Eq | 1.94 | Sales Q/Q | 0.72% | SMA50 | -12.45% | Rel Volume | 2.45 | Prev Close | 15.10 |
| Employees | 4,427 | LT Debt/Eq | 1.81 | Earnings | Oct 29 | SMA200 | 9.20% | Avg Volume | 884.58K | Price | 15.22 |
| IPO Date | Aug 16, 1995 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 16.54% 0.29% | Net Debt/EBITDA | 7.34 | Volume | 2,169,061 | Change | 0.79% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-28-26 | Initiated | UBS | Neutral | $19 |
| Jul-16-26 | Reiterated | Truist Securities | Hold | $12 → $19 |
| Jul-08-26 | Reiterated | BMO Capital | $19 | |
| Jun-18-26 | Reiterated | Argus Research | Hold | $25 |
| May-28-26 | Upgrade | Citigroup | Sell → Neutral | |
| Apr-15-26 | Downgrade | Argus Research | Buy → Hold | |
| Apr-15-26 | Reiterated | Truist Securities | Hold | $15 → $12 |
| Oct-15-25 | Reiterated | Truist Securities | Hold | $26 → $15 |
| Mar-31-25 | Upgrade | Argus Research | Hold → Buy | |
| Oct-07-24 | Upgrade | BTIG | Sell → Neutral | $22 → $20 |
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,648 | 1,635 | 1,611 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 763 | 790 | 728 | — | — | — | — | — | — | |
| Gross Profit | 885 | 845 | 882 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 688 | 700 | 717 | — | — | — | — | — | — | |
| Research and Development | 95 | 99 | 115 | — | — | — | — | — | — | |
| Other Operating Expense | -554 | -22 | 22 | — | — | — | — | — | — | |
| Operating Income | 655 | 68 | 28 | — | — | — | — | — | — | |
| Interest Expense | 97 | 86 | 71 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -560 | -546 | 24 | — | — | — | — | — | — | |
| Net Income Before Taxes | 0 | -564 | -18 | — | — | — | — | — | — | |
| Income Taxes | 7 | -47 | -11 | — | — | — | — | — | — | |
| Consolidated Net Income | -8 | -516 | -7 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -8 | -516 | -7 | — | — | — | — | — | — | |
| Net Income | -8 | -516 | -7 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.09 | -6.73 | -0.09 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.09 | -6.73 | -0.09 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.09 | -6.73 | -0.09 | — | — | — | — | — | — | |
| EBITDA | 249 | -326 | 193 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.72 | 0.58 | 1.08 | — | — | — | — | — | — | |
| Gross Margin | 53.70 | 51.68 | 54.75 | — | — | — | — | — | — | |
| Operating Margin | 39.75 | 4.16 | 1.74 | — | — | — | — | — | — | |
| Net Margin | -0.49 | -31.56 | -0.43 | — | — | — | — | — | — | |
| Shares Outstanding | 78 | 77 | 77 | — | — | — | — | — | — | |
| Market Capitalization | 1,187 | 956 | 1,746 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Singh Harvinder | EVP & PRESIDENT, INTERNATIONAL | Mar 11 '26 | Option Exercise | 0.00 | 37,844 | 0 | 40,612 | Mar 12 |
| Singh Harvinder | EVP & PRESIDENT, INTERNATIONAL | Mar 10 '26 | Option Exercise | 0.00 | 1,216 | 0 | 23,152 | Mar 12 |
| Poul Mojdeh | President & CEO | Jan 06 '26 | Option Exercise | 0.00 | 1,390 | 0 | 1,390 | Jan 07 |
| GRAVES JEFFREY A | Director | Nov 05 '25 | Buy | 11.35 | 9,000 | 102,150 | 41,086 | Nov 06 |
| Singh Harvinder | EVP & PRESIDENT, INTERNATIONAL | Oct 12 '25 | Option Exercise | 0.00 | 11,965 | 0 | 25,217 | Oct 14 |
| Singh Harvinder | EVP & PRESIDENT, INTERNATIONAL | Mar 11 '25 | Option Exercise | 0.00 | 2,356 | 0 | 4,391 | Mar 13 |
| Singh Harvinder | EVP & PRESIDENT, INTERNATIONAL | Mar 10 '25 | Option Exercise | 0.00 | 1,180 | 0 | 2,359 | Mar 11 |
| Schwartz Eric | EVP, Chief Legal Officer & Sec | Dec 03 '24 | Sale | 24.59 | 4,070 | 100,102 | 59,511 | Dec 04 |
| McBreen Michael J. | EVP & President, CSS | Dec 02 '24 | Sale | 24.16 | 1,700 | 41,064 | 56,182 | Dec 03 |
| De Witte Jan | President & CEO | Nov 01 '24 | Option Exercise | 0.00 | 9,814 | 0 | 28,164 | Nov 04 |
| Mosebrook Jeffrey | SVP, Fin & Princ Acct Officer | Aug 19 '24 | Sale | 21.58 | 1,191 | 25,701 | 36,088 | Aug 20 |
| ESSIG STUART | Exec. Chairman of the Board | May 23 '24 | Buy | 28.49 | 52,641 | 1,499,979 | 487,922 | May 24 |
| HILL BARBARA B | Director | May 21 '24 | Buy | 27.40 | 36,350 | 995,816 | 36,350 | May 22 |
| De Witte Jan | President & CEO | Mar 11 '24 | Option Exercise | 0.00 | 205 | 0 | 18,555 | Mar 13 |
| De Witte Jan | President & CEO | Mar 10 '24 | Option Exercise | 0.00 | 346 | 0 | 18,696 | Mar 12 |